Loading
KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane.
Open Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.19, genetic association 0.24, clinical 0.76).
In plain words · KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient.
No product in this corpus aims at KCNA4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNA4: RNA tissue enhanced (adrenal gland 6 nTPM, brain 8 nTPM); no normal tissue stained high; highest cancer staining pancreatic cancer (1 of 11 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNA4 tissue; Open Targets ENSG00000182255 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Philipson L.H. et al, Nucleic Acids Res, 1990, "Sequence of a human fetal skeletal muscle potassium channel cDNA related to RCK4". Source.
Sources: HGNC HGNC:6222 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P22459 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000182255 (association with cancer (MONDO_0004992) 0.51; (GraphQL API, CC0))
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Location: Cell membrane; Cell projection, axon (UniProt). Locus 11p14.1 (HGNC).
RNA: tissue enhanced (adrenal gland 6 nTPM, brain 8 nTPM), detected in some normal tissues.
No normal tissue stained high; medium in Adrenal gland, Cerebellum, Cerebral cortex, Hippocampus.
Medium only: breast cancer, lung cancer, melanoma, ovarian cancer.
HPA KCNA4 tissue · HPA KCNA4 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNA4" OR ABSTRACT:"KCNA4" OR TITLE:"potassium voltage-gated channel subfamily A member 4" OR ABSTRACT:"potassium voltage-gated channel subfamily A member 4" OR TITLE:"Potassium voltage-gated channel subfamily A member 4" OR ABSTRACT:"Potassium voltage-gated channel subfamily A member 4" OR TITLE:"Kv1.4" OR ABSTRACT:"Kv1.4" OR TITLE:"HK1" OR ABSTRACT:"HK1" OR TITLE:"HPCN2" OR ABSTRACT:"HPCN2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNA4, not a curated reading list.